Monoclonal antibodies against AGR2 markedly reduce tumor growth and metastasis in pancreatic ductal adenocarcinoma, but this reduction has only been observed in preclinical mouse models (25). Here, AGR2 is linked to pancreatic ductal adenocarcinoma.